Overview

PDM08 Clinical Trial in Advanced Solid Tumors

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

This phase I study in adult patients with advanced solid tumours is designed to evaluate toxicity, drug exposure (pharmacokinetics) and drug action (pharmacodynamics) of a new molecule, PDM08, administered twice a week cycles of 4 weeks. This drug has shown antitumoral activity in several murine cancer models.

Phase:

Phase 1

Details

Lead Sponsor:

Prodimed S.A.

Treatments:

Bromides